DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,284,263 B1 Place (45) Date of Patent: Sep

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,284,263 B1 Place (45) Date of Patent: Sep USOO6284263B1 (12) United States Patent (10) Patent No.: US 6,284,263 B1 Place (45) Date of Patent: Sep. 4, 2001 (54) BUCCAL DRUG ADMINISTRATION IN THE 4,755,386 7/1988 Hsiao et al. TREATMENT OF FEMALE SEXUAL 4,764,378 8/1988 Keith et al.. DYSFUNCTION 4,877,774 10/1989 Pitha et al.. 5,135,752 8/1992 Snipes. 5,190,967 3/1993 Riley. (76) Inventor: Virgil A. Place, P.O. Box 44555-10 5,346,701 9/1994 Heiber et al. Ala Kahua, Kawaihae, HI (US) 96743 5,516,523 5/1996 Heiber et al. 5,543,154 8/1996 Rork et al. ........................ 424/133.1 (*) Notice: Subject to any disclaimer, the term of this 5,639,743 6/1997 Kaswan et al. patent is extended or adjusted under 35 6,180,682 1/2001 Place. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/626,772 Primary Examiner Thurman K. Page ASSistant Examiner-Rachel M. Bennett (22) Filed: Jul. 27, 2000 (74) Attorney, Agent, or Firm-Dianne E. Reed; Reed & Related U.S. Application Data ASSciates (62) Division of application No. 09/237,713, filed on Jan. 26, (57) ABSTRACT 1999, now Pat. No. 6,117,446. A buccal dosage unit is provided for administering a com (51) Int. Cl. ............................. A61F 13/02; A61 K9/20; bination of Steroidal active agents to a female individual. A61K 47/30 The novel buccal drug delivery Systems may be used in (52) U.S. Cl. .......................... 424/435; 424/434; 424/464; female hormone replacement therapy, in female 514/772.3 contraception, to treat female Sexual dysfunction, and to treat or prevent a variety of conditions and disorders which (58) Field of Search ..................................... 424/430, 434, are responsive to the active agents discussed herein. The 424/435, 464; 514/772.3 buccal dosage unit comprises a progestin, an estrogen and (56) References Cited optionally an androgenic agent, as well as a polymeric carrier that bioerodes and provides for delivery of the active U.S. PATENT DOCUMENTS agents throughout a predetermined drug delivery period. 4,507,323 3/1985 Stern. 4,521,421 6/1985 Foreman. 40 Claims, 2 Drawing Sheets O U.S. Patent Sep. 4, 2001 Sheet 1 of 2 US 6,284,263 B1 U.S. Patent Sep. 4, 2001 Sheet 2 of 2 US 6,284,263 B1 US 6,284,263 B1 1 2 BUCCAL DRUGADMINISTRATION IN THE (New York: Plenum Press, 1983). In such treatments, estro TREATMENT OF FEMALE SEXUAL gen is administered orally, parenterally (e.g., by injection), DYSFUNCTION or topically. With oral administration, as is true with the oral administration of many Steroid hormones, estrogens tend to CROSS-REFERENCE TO RELATED be inactivated; estradiol, for example, is converted to estriol APPLICATIONS and estrone and then conjugated to glucuronic acid or Sulfate. Additionally, estrogens also impair hepatic Secretory This application is a divisional of U.S. patent application activity. This “first pass” effect may lead to an undesirable Ser. No. 09/237,713, filed Jan. 26, 1999, now U.S. Pat. No. increase in the production of certain coagulation factors and 6,117,446. other biologically important compounds by the liver. Parenterally administered estrogen avoids the aforemen TECHNICAL FIELD tioned problems associated with oral administration. However, all estrogen-based therapies are known to increase This invention relates generally to pharmaceutical com the risk of endometrial hyperplasia and cancer, as well as the positions and methods for administering pharmacologically risk of breast cancer, in treated individuals. active agents. More particularly, the invention relates to 15 Because of the increased risk of endometrial hyperplasia buccal drug delivery, and to a buccal dosage unit and method and endometrial cancer encountered with unopposed estro for administering a combination of Steroidal active agents, gen therapies, estrogen/progestin combinations have been e.g., for female hormone replacement therapy, female employed. However, Such therapies, as is well known, result contraception, treatment of female Sexual dysfunction, and in a number of Side effects, including uterine bleeding and the like. the continuation of menstrual periods. Accordingly, there remains a need in the art to provide Safer and more effective BACKGROUND treatments for administering active agents Suitable for female hormone replacement therapy. Androgens are the hormones that cause most of the The present invention is directed in part to the aforemen masculinizing changes that occur in males during puberty. 25 tioned need in the art, and provides highly effective hormone Harrison's Principles of Internal Medicine, 12th Edition replacement therapy for women in need of Such treatment. (New York, N.Y.: McGrawHill, Inc., 1991). However, low The invention involves the use of a pharmaceutical compo levels of androgens are also present in normal females. Sition in the form of a drug dosage unit to be applied to the Testosterone and other androgens are Secreted by the ovary buccal mucosa. In contrast to prior methods for effecting and the adrenal cortex. See, e.g., Goodman & Gilman's The hormone replacement, the present invention avoids both Pharmacological Basis of Therapeutics, 9th Edition (New gastrointestinal degradation of the drug and the “first pass” York, N.Y.: McGraw Hill, Inc., 1996). Dehydroepiandros effect in the liver encountered with oral formulations, and terone (DHEA) and androstenedione are also synthesized by enables the use of Smaller doses of active agents (and thus both the adrenal gland and the Ovary and can be converted avoids the Side effects associated with conventional to testosterone or estrogen in peripheral tissues. The daily 35 formulations). In addition, when an androgenic agent is rate of production of testosterone in Women is on the order included, as in the preferred embodiment herein, essentially of 0.25 mg, about half of which is derived from the meta complete hormone replacement is provided. That is, with bolic conversion of androstenedione to testosterone at respect to the latter point, estrogen/progestin therapies do extraglandular sites. The plasma concentration of testoster not in fact provide “replacement of the complete hormone one in women alters with the menstrual cycle and ranges 40 profile of the premenopausal woman, because, as discussed from 15 to 65 nanogam/deciliter (ng/dl). AS with estrogen, above, androgens are also present in premenopausal women. testosterone levels peak at the preovulatory and luteal phases In a preferred embodiment, then, the present invention calls of the cycle. At menopause, plasma androgen and estrogen for one or more androgenic agents to be administered along levels are reduced but not completely absent in Women. with a progestin and an estrogen. Alteration in the hormone profile is believed to be an 45 The method and compositions of the invention may also underlying cause of menopausal Symptoms in Women, be used to treat other conditions for which the disclosed including vasomotor instability (“hot flash”), atrophy of the hormone combination is useful. For example, the novel drug urogenital epithelium and skin, decreased size of the breasts dosage units can be used to treat female Sexual dysfunction, and osteoporosis. See, e.g., Harrison's Principles of Internal to effect female contraception, to improve Vaginal muscle Medicine, Supra. 50 tone and tissue health, and to enhance vaginal lubrication. Alteration in normal hormonal levels can also cause Drug therapy for treating female Sexual dysfunction has Sexual dysfunction. For example, estrogen deficiency, caus been described. For example, U.S. Pat. No. 4,507.323 to ing vaginal atrophy and dySpareunia, is a common cause of Stem describes the use of the anxiolytic m-chloro-O-t- Sexual dysfunction. Dyspareunia is thought to affect butylamino-propiophenone in the treatment of Sexual dyS approximately 40% of women; it has been estimated that 55 function in male and female individuals. Pharmaceutical over 40 million female individuals will suffer dyspareunia at compositions containing the agent are described, which are Some time in their lives. On the order of twenty-five million presented in discrete units, e.g., cachets, tablets, capsules, Women will experience dySpareunia in the peri- and post ampules and Suppositories for oral or anal delivery of the menopausal periods (Kelly (1992) Clinical Practice and agent. Additionally, U.S. Pat. No. 4,521,421 to Foreman Sexuality 8(8):2; and Sato et al. (1992) Clinical Practices in 60 describes the treatment of Sexual dysfunction in male and Sexuality 8(5):1. female individuals using the Stereoisomers of octahydro EStrogen therapy is commonly used in the pharmacologi pyrimidoquinoline agents, centrally acting dopamine ago cal treatment of altered hormone profiles or Sexual dysfunc nists. U.S. Pat. No. 5,190,967 to Riley describes the treat tion in Women. Estrogen-based therapies are generally used ment of Sexual disorders in male and female individuals to increase mucous production, provide vasodilator effects, 65 using heterocyclic benzodioxinopyrrole compounds, which, and/or to increase the general health of the vagina. Nadelson like the drugs described in the aforementioned patents, are et al., eds., Treatment Interventions in Human Sexuality centrally acting agents. US 6,284,263 B1 3 4 Drug therapy involving buccal administration of Steroid and for enhancing vaginal lubrication, each of Such methods hormones has also been described. For example, U.S. Pat. involving buccal administration of a pharmaceutical com No. 4,755,386 to Hsiao et al. generally describes the buccal position as described herein to a woman in need of Such administration of various medicaments, including estrogens, treatment. proge Stins and androgens, combinations of the Additional objects, advantages and novel features of the medicaments, however, are not contemplated. Furthermore, invention will be set forth in part in the description which the buccal tablets of Hsiao et al., weighing on the order of follows, and in part will become apparent to those sldlled in 50 mg, contain adhesive, disintegrant and excipient in the art upon examination of the following, or may be learned addition to the active agent, with the inactive ingredients by practice of the invention.
Load more

Recommended publications
  • Estrone with Pipera- with an Anabolic Steroid and a Progestogen for Osteoporosis
    Estradiol/Ethinylestradiol 2101 Estrapronicate (rINN) menopausal atrophic vaginitis and kraurosis vulvae. A dose of Estrapronicato; Estrapronicatum. Oestradiol 17-nicotinate 3- 500 micrograms may be given as a 0.01% or 0.1% cream or as a pessary; initial treatment may be given once daily, then reduced propionate. O to twice each week. NH CH3 Эстрапроникат Estriol has also been given orally for infertility (p.2080) caused HN C27H31NO4 = 433.5. by poor cervical penetration, in a dose of 0.25 to 1 mg daily on H CAS — 4140-20-9. days 6 to 15 of the menstrual cycle. O Estriol succinate has also been given orally in the treatment of HO HH menopausal disorders. The sodium succinate salt has been used S N parenterally in the treatment of haemorrhage and thrombocyto- O penia. O Preparations Pharmacopoeias. In Br. and US. BP 2008: Estriol Cream. BP 2008 (Estropipate). A white or almost white crystalline pow- Proprietary Preparations (details are given in Part 3) O O der. Very slightly soluble in water, in alcohol, in chloroform, and Arg.: Colpoestriol; Orgestriol; Austral.: Ovestin; Austria: Ortho-Gynest; in ether. H3C Ovestin; Styptanon; Belg.: Aacifemine; Ortho-Gynest; Braz.: Estriopax; Hormocervix; Hormoniol; Ovestrion; Styptanon; Chile: Ovestin; Sina- USP 31 (Estropipate). A white to yellowish-white fine crystal- pause; Vacidox; Cz.: Ortho-Gynest; Ovestin; Denm.: Ovestin; Fin.: Oves- line powder, odourless or may have a slight odour. Very slightly H tin; Pausanol; Fr.: Gydrelle; Physiogine; Trophicreme; Ger.: Cordes Estriol; soluble in water, in alcohol, in chloroform, and in ether; soluble Gynasan†; OeKolp; Oestro-Gynaedron M; Ortho-Gynest; Ovestin; Syna- 1 in 500 of warm alcohol; soluble in warm water.
    [Show full text]
  • Magnesium Causes Nitric Oxide Independent Coronary Artery Vasodilation in Humans Heart: First Published As 10.1136/Hrt.86.2.212 on 1 August 2001
    212 Heart 2001;86:212–216 Magnesium causes nitric oxide independent coronary artery vasodilation in humans Heart: first published as 10.1136/hrt.86.2.212 on 1 August 2001. Downloaded from H Teragawa, M Kato, T Yamagata, H Matsuura, G Kajiyama Abstract Objective—To determine how magnesium aVects human coronary arteries and whether endothe- lium derived nitric oxide (EDNO) is involved in the coronary arterial response to magnesium. Design—Quantitative coronary angiography and Doppler flow velocity measurements were used to determine the eVects of the nitric oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA) on magnesium induced dilation of the epicardial and resistance coronary arteries. Setting—Hiroshima University Hospital a tertiary cardiology centre. Patients—17 patients with angiographically normal coronary arteries. Interventions—Magnesium sulfate (MgSO4) (0.02 mmol/min and 0.2 mmol/min) was infused for two minutes into the left coronary ostium before and after intracoronary infusion of L-NMMA. Main outcome measures—Diameter of the proximal and distal segments of the epicardial cor- onary arteries and coronary blood flow. Results—At a dose of 0.02 mmol/min, MgSO4 did not aVect the coronary arteries. At a dose of 0.2 mmol/min, MgSO4 caused coronary artery dilation (mean (SEM) proximal diameter 3.00 (0.09) to 3.11 (0.09) mm; distal 1.64 (0.06) to 1.77 (0.07) mm) and increased coronary blood flow (79.3 (7.5) to 101.4 (9.9) ml/min, p < 0.001 v baseline for all). MgSO4 increased the changes in these parameters after the infusion of L-NMMA (p < 0.001 v baseline).
    [Show full text]
  • THE ACCUMULATION and DISTRIBUTION of EVANS BLUE in the KIDNEY of RATS FED NORMAL OR LOW MAGNESIUM DIETS by George Williams Seign
    THE ACCUMULATION AND DISTRIBUTION OF EVANS BLUE IN THE KIDNEY OF RATS FED NORMAL OR LOW MAGNESIUM DIETS by George Williams Seignious, IV Thesis submitted to the Graduate Faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in ! Biochemistry and Nutrition APPROVED: G. E. Bunce, Chairman R. E. Webb ______ fl" ________ M;O. ......... ..;:;...; ___'"";:,....:; __.;..,. ___ _ _.. ''-.::;,,/ ___ , _______ ,_.._~_ M. H. Samli R. G. Saacke August, 1973 Blacksburg, Virginia . l\CKNOWLEDGMEN',rS The author of this thesis would like to e~press his deepest thanks and gra'titU;de to for his.continued help, advice, and . ·. .. : .. - understanding which made this thesis possible •. A special note of ·"· thanks is expressed.to whos_e invaluable help, advice arid suggestions aided greatly the author's efforts. The author would also like to thank for his. help and advice in the lab and all the other graduate students who made the author's stay at Virginia.Tech i{ very pleasant _one. Thanks is expressed to the author's wife, , for .her love, understanding, encouragement, and typing which· enabled the completion of this thesis. Also the author would like.to thank his parents for their lc;rving support and financial assistance. ii 'TABLE OF CONTENTS ACKNOWLEDGMENTS ii. TABLE OF CONTENTS . iii I,.IST OF TABLES iv LIST OF FIGURES Vi LIST OF SELECTED CHEMICAL STRUCTURES vii LIST OF·ABBREVIATIONS viii INTRODUCTION 1 LITERATURE REVIEW 5 EXPERIMENTAL PROCEDURES RESULTS 33 DISCUSSION 74 SUMMARY 82 REFERENCES 85 VITA 88 iii ~· ,,;.
    [Show full text]
  • Record of Reasons for 16-18 November 1999 Meeting
    1 NATIONAL DRUGS AND POISONS SCHEDULE COMMITTEE MEETING 25 – 16-18 November 1999 RECORD OF REASONS FOR AMENDMENT TO THE STANDARD FOR THE UNIFORM SCHEDULING OF DRUGS AND POISONS AGRICULTURAL, VETERINARY AND DOMESTIC CHEMICALS Buprofezin – Schedule required Amendment and Reasons The decision below was based on buprofezin’s toxicological profile, in particular its acute oral toxicity. A cut-off to exempt at a concentration of 40% was agreed because of the reduced oral toxicity at this concentration and the ability of safety directions and warning statements applied through the registration system for agricultural and veterinary chemicals to adequately address the slight eye irritation which was attributed to the product formulation. Schedule 5 – New entry BUPROFEZIN except in preparations containing 40 per cent or less of buprofezin. Copper hydroxide - progression of foreshadowed decision to include copper hydroxide in Schedule 6 with cut-off to Schedule 5 at 50 per cent and to exempt at 12.5 per cent. Amendment and Reasons The amendment below was based on the acute oral toxicity of copper hydroxide, its severe eye irritancy / corrosivity, and the possibility of products containing copper hydroxide being accessible in domestic situations and therefore presenting a risk of accidental ingestion. Schedule 6 – New entry COPPER HYDROXIDE except: (a) when included in Schedule 5; or (b) in preparations containing 12.5 per cent or less of copper hydroxide. Schedule 5 – New entry COPPER HYDROXIDE in preparations containing 50 per cent or less of copper hydroxide except in preparations containing 12.5 per cent or less of copper hydroxide. Cyhexatin - Review of Appendix F warning statements and Appendix J rider.
    [Show full text]
  • Androgenic and Anabolic Activities of Some Newly Synthesized Epiandrosterone and Progesterone Derivatives
    Scientia Pharmazeutica (Sci. Pharm.) 68, 141-1 57 (2000) O Osterreichische Apotheker-Verlagsgesellschaft m. b. H, Wien, Printed in Austria Androgenic and Anabolic Activities of Some Newly Synthesized Epiandrosterone and Progesterone Derivatives. Y. A. ~aklaai"and M. M. ~osseir'~' Abstract Derivatives of eplandrosterone and progesterone were synthesized. The androgenic and the anabolic activities of some of tlieln were investigated on prepubertal male albino rats of 21 days old by:-i determining tlie weight gain of the body, levator ani muscle, ventral prostate gland, testis, selniilal vesicles, vas deferens and epididymis, ii- esti~natioi~of serum luteinizing (LH) hor~none,iii- liistopatliological examination of the testis and ventral prostate glands. The results from this study showed that the presence of an appended substituted 2- aminopyridine ring at the C- 17 of testosterone gave the maximuin a~idrogenicactivity, whereas the presence of a substituted piperidine ring fused to ring D of 5 a- androstane exhibited tlie maxiini~inanabolic activity. However, filsio~~of a pyrazoline moiety with the ring D of 5 a- androstane led to a compo~undwith considerable androgenic and anabolic act~v~ty. Keywords: epiandrosterone, progesterone, a~idrogenicactivity, anabolic activity, prepubertal rat, inale sex accessory glands, luteinizing horinone, I~istopatl~ology Introduction A~idrogensare a class of steroids responsible for tlie primary and secondary sex characteristics of the male. In addition, these steroids have bee11 found to possess potent anabolic promoting properties. The androgens are formed by the Leydig cells of the testis which is regulated by tlie gonadotropic luteinizing hormone (LH). The latter is secreted by tlie (J - cells of the anterior pitiltary gland under tlie control of the liypotlialainic gonadotropin - releasing l~oni~one.LH polypeptide -cliaiii is bioclie~nically unique and confers the LH biological and il~~~~~l~~~ologicnlspecificity "'".
    [Show full text]
  • To See References
    Longevity & Bioidentical Hormones Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab. 2009 May;94(5):1732-9. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004 Aug;90(8):871-6. Besson A, Salemi S, Gallati S, et al. Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab. 2003 Aug;88(8):3664- 7. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2004 Jan;89(1):114-120. Moffat SD, Zonderman AB, Metter EJ, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004 Jan 27;62(2):188-193. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007 Dec 4;116(23):2694-701. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004 Jul;89(7):3313-3318. Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III).
    [Show full text]
  • REVIEW Effects of Androgens on Cardiovascular Remodeling
    1 REVIEW Effects of androgens on cardiovascular remodeling Yasumasa Ikeda1,2, Ken-ichi Aihara2, Sumiko Yoshida2, Masashi Akaike3 and Toshio Matsumoto2 Departments of 1Pharmacology, 2Medicine and Bioregulatory Sciences and 3Medical Education, The University of Tokushima, Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan (Correspondence should be addressed to K Aihara; Email: [email protected]) Abstract Androgens, the male sex hormones, exert various biological cardiovascular mortality. However, the influence of androgens effects on many target organs through the transcriptional effects on the cardiovascular system has not been fully elucidated. of the nuclear androgen receptor (AR). ARs are expressed not Toclarify this issue, we analyzed the effects of administration of only in classical target organs, such as the brain, genital organs, angiotensin II and doxorubicin, an anticancer agent, in a bone, and skeletal muscles, but also in the cardiovascular loading model in male wild-type and AR-deficient mice. In system. Because the female sex hormones estrogens are well- this review, we focus on the actions of androgens as potential known to protect against cardiovascular disease, sex has targets for the prevention of cardiovascular diseases in males. been considered to have a significant clinical impact on Journal of Endocrinology (2012) 214, 1–10 Introduction In addition, previous studies have shown that testosterone replacement tends to increase cardiovascular risk among Cardiovascular disease remains a major cause of death in both men of all ages (Calof et al. 2005, Haddad et al. 2007, womenandmenworldwideandappearstoincrease Fernandez-Balsells et al. 2010). On the other hand, recent morbidity and mortality in industrial countries.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Effects of Zilpaterol and Melengestrol Acetate On
    EFFECTS OF ZILPATEROL AND MELENGESTROL ACETATE ON BOVINE SKELETAL MUSCLE GROWTH AND DEVELOPMENT by ERIN KATHRYN SISSOM B.S., California State University, Fresno, 2002 M.S., Kansas State University, 2004 AN ABSTRACT OF A DISSERTATION submitted in partial fulfillment of the requirements for the degree DOCTOR OF PHILOSOPHY Department of Animal Sciences and Industry College of Agriculture KANSAS STATE UNIVERSITY Manhattan, Kansas 2009 Abstract Zilpaterol (ZIL) is a β-adrenergic receptor (β-AR) agonist that has been recently approved for use in feedlot cattle to improve production efficiencies and animal performance. One of the mechanisms through which this occurs is increased skeletal muscle growth. Therefore, two experiments were conducted to determine the effects of ZIL both in vivo and in vitro . In the first experiment, ZIL addition to bovine satellite cells resulted in a tendency to increase IGF-I mRNA and increased myosin heavy chain IIA (MHC) mRNA with 0.001 µ M and decreased MHC mRNA with 0.01 and 10 µ M. There were no effects of ZIL on protein synthesis or degradation. In myoblast cultures, there was a decrease in all three β-AR mRNA, and this was also reported in western blot analysis with a reduction in β2-AR expression due to ZIL treatment. In myotubes, there was an increase in β2-AR protein expression. In the second and third experiment, ZIL improved performance and carcass characteristics of feedlot steers and heifers. Additionally, ZIL decreased MHC IIA mRNA in semimembranosus muscle tissue collected from both steers and heifers. An additional part of the third study was conducted to determine the effects of melengestrol acetate (MGA) on bovine satellite cell and semimembranosus muscle gene expression.
    [Show full text]
  • Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol Acetate Is Also Used in the Treatment of Ano- 16
    Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol acetate is also used in the treatment of ano- 16. Mwamburi DM, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar As for progestogens in general (see Progesterone, rexia and cachexia (see below) in patients with cancer results in 2 months. Clin Infect Dis 2004; 38: 895–902. p.2125). The weight gain that may occur with meges- or AIDS. The usual dose is 400 to 800 mg daily, as tab- 17. Grunfeld C, et al. Oxandrolone in the treatment of HIV-associ- ated weight loss in men: a randomized, double-blind, placebo- trol acetate appears to be associated with an increased lets or oral suspension. A suspension of megestrol ace- controlled study. J Acquir Immune Defic Syndr 2006; 41: appetite and food intake rather than with fluid reten- tate that has an increased bioavailability is also availa- 304–14. tion. Megestrol acetate may have glucocorticoid ef- ble (Megace ES; Par Pharmaceutical, USA) and is Hot flushes. Megestrol has been used to treat hot flushes in fects when given long term. given in a dose of 625 mg in 5 mL daily for anorexia, women with breast cancer (to avoid the potentially tumour-stim- cachexia, or unexplained significant weight loss in pa- ulating effects of an oestrogen—see Malignant Neoplasms, un- Effects on carbohydrate metabolism. Megestrol therapy der Precautions of HRT, p.2075), as well as in men with hot 1-3 4 tients with AIDS. has been associated with hyperglycaemia or diabetes mellitus flushes after orchidectomy or anti-androgen therapy for prostate in AIDS patients being treated for cachexia.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Pharmaceuticals and Endocrine Active Chemicals in Minnesota Lakes
    Pharmaceuticals and Endocrine Active Chemicals in Minnesota Lakes May 2013 Authors Mark Ferrey Contributors/acknowledgements The MPCA is reducing printing and mailing costs This report contains the results of a study that by using the Internet to distribute reports and characterizes the presence of unregulated information to wider audience. Visit our website contaminants in Minnesota’s lakes. The study for more information. was made possible through funding by the MPCA reports are printed on 100 percent post- Minnesota Clean Water Fund and by funding by consumer recycled content paper manufactured the U.S. Environmental Protection Agency without chlorine or chlorine derivatives. (EPA), which facilitated the sampling of lakes for this study. The Minnesota Pollution Control Agency (MPCA) thanks the following for assistance and advice in designing and carrying out this study: Steve Heiskary, Pam Anderson, Dereck Richter, Lee Engel, Amy Garcia, Will Long, Jesse Anderson, Ben Larson, and Kelly O’Hara for the long hours of sampling for this study. Cynthia Tomey, Kirsten Anderson, and Richard Grace of Axys Analytical Labs for the expert help in developing the list of analytes for this study and logistics to make it a success. Minnesota Pollution Control Agency 520 Lafayette Road North | Saint Paul, MN 55155-4194 | www.pca.state.mn.us | 651-296-6300 Toll free 800-657-3864 | TTY 651-282-5332 This report is available in alternative formats upon request, and online at www.pca.state.mn.us. Document number: tdr-g1-16 Contents Contents ...........................................................................................................................................
    [Show full text]